With Mylan now halfway through its Perrigo tender offer period, the company tried once again on Tuesday to make its case for shareholders. The multiple it's offering is attractive, Mylan's execs insisted--and that's why no rival bidders have stepped up to top it.
Israeli drug developer Protalix BioTherapeutics is backing away from its sole approved drug, selling the majority rights to partner Pfizer and pledging to invest the proceeds in its pipeline.
DNA testing outfit DNA Diagnostics is selling out to European healthcare investor GHO Capital for €104 million ($118 million), allowing GHO to cash in on the genetic testing market and expand its international footprint while increasing DDC's global reach.
Novartis is acquiring more of stem cell partner Gamida Cell but steering away from buying the company outright as it blueprints a Phase III trial for its blood cancer therapy.
Blackstone, a global private equity heavyweight, signed on to buy BioMed Realty for $8 billion, picking up one of the life sciences industry's largest leasers of lab and office space.
Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.
Boston Scientific announced that it has obtained an exclusive $200 million option to acquire Israel's MValve Technologies, maker of a transcatheter mitral valve replacement system for mitral regurgitation. Boston Scientific also said it is providing additional financing to the company in anticipation of a first in-human clinical trial.
Some analysts have never been all that keen on Mylan's hostile quest for Perrigo. But some forthcoming obstacles for Perrigo's businesses now have at least one questioning the deal's logic even further.
The venture capital market remains weak, but M&A activity is still strong and R&D spending is on an upward trend, conclude two state-of-the-industry reports released by EY (formerly Ernst & Young) and EvaluateMedTech and at the annual AdvaMed industry conference.
HeartWare was up about 5% in early trading on the news that activist investor Engaged Capital is opposing its acquisition of mitral valve player Valtech Cardio--and is seeking a renewed focus on LVAD with a possible sale of the company. If the deal is not terminated, Engaged Capital said it will continue to oppose it and seek board representation.